© 2021 MJH Life Sciences and Neurology Live. All rights reserved.
© 2021 MJH Life Sciences™ and Neurology Live. All rights reserved.
October 13, 2018
Cellular therapies have the potential to make a meaningful difference for patients with neurological disorders, if used correctly.
October 12, 2018
IncobotulinumtoxinA significantly reduced unstimulated salivary flow rate for patients with sialorrhea.
Patisiran maintained improvements in mNIS+7 and rapidly halted neurologic disease progression in hATTR amyloidosis.
October 11, 2018
Subcutaneous immunoglobulin is an effective and well-tolerated alternative to intravenous immunoglobulin for myasthenia gravis.
Eculizumab showed sustained activity and tolerability through 3 years for generalized myasthenia gravis.